Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Batia Stark"'
Autor:
Ursula Creutzig, Martin Zimmermann, Michael N. Dworzak, Brenda Gibson, Rienk Tamminga, Jonas Abrahamsson, Shau-Yin Ha, Henrik Hasle, Alexey Maschan, Yves Bertrand, Guy Leverger, Christine von Neuhoff, Bassem Razzouk, Carmelo Rizzari, Petr Smisek, Owen P. Smith, Batia Stark, Dirk Reinhardt, Gertjan L. Kaspers
Publikováno v:
Haematologica, Vol 99, Iss 9 (2014)
The prognostic significance of early response to treatment has not been reported in relapsed pediatric acute myeloid leukemia. In order to identify an early and easily applicable prognostic factor allowing subsequent treatment modifications, we asses
Externí odkaz:
https://doaj.org/article/1665833acc1248498f4128737c2867b0
Autor:
Marjolein Blink, Martin Zimmermann, Christine von Neuhoff, Dirk Reinhardt, Valerie de Haas, Henrik Hasle, Maureen M. O’Brien, Batia Stark, Julie Tandonnet, Andrea Pession, Katerina Tousovska, Daniel K.L. Cheuk, Kazuko Kudo, Takashi Taga, Jeffrey E. Rubnitz, Iren Haltrich, Walentyna Balwierz, Rob Pieters, Erik Forestier, Bertil Johansson, Marry M. van den Heuvel-Eibrink, C. Michel Zwaan
Publikováno v:
Haematologica, Vol 99, Iss 2 (2014)
Myeloid leukemia of Down syndrome has a better prognosis than sporadic pediatric acute myeloid leukemia. Most cases of myeloid leukemia of Down syndrome are characterized by additional cytogenetic changes besides the constitutional trisomy 21, but th
Externí odkaz:
https://doaj.org/article/7146248388fd45c3801e2de3bbbbe378
Autor:
Batia Stark, Dina Attias, Herzel Gabriel, Shai Izraeli, Myriam Weyl Ben-Arush, Gali Avrahami, Aya Abramov, Ronit Elhasid, Michael Wientraub, Amos Toren, Yoav Burstein, Ami Ballin, Isaac Yaniv, Joseph Kapelushnik, Sarah Elitzur, Nira Arad, Smadar Avigad, Michal Hameiri-Grossman, Bella Bielorai, Dalia Sthoeger, Ronit Nirel
Publikováno v:
Pediatric bloodcancerREFERENCES. 67(1)
BACKGROUND Therapy outcomes for childhood acute lymphoblastic leukemia (ALL) had substantially improved in the last decades, but variability across racial and ethnic groups was identified in some clinical studies. In this study, we aimed to investiga
Autor:
Asaf Lebel, Smadar Avigad, Oshrit Kordi, Isaac Yaniv, Jan Trka, Drorit Luria, Sarah Elitzur, Hadar Mirsky, Anat Ohali, Keren Shichrur, Yona Kodman, Dafna Gaash, Eva Fronkova, Gertjan J.L. Kaspers, Iedan Rn Verly, Galia Avrahami, Gil Gilad, Batia Stark, Marta Jeison, Michal Hameiri-Grossman, Jacqueline Cloos
Publikováno v:
Genes, Chromosomes and Cancer. 55:328-339
Our aim was to identify miRNAs that can predict risk of relapse in pediatric patients with acute lymphoblastic leukemia (ALL). Following high-throughput miRNA expression analysis (48 samples), five miRs were selected for further confirmation performe
Autor:
Moshe Phillip, Gil Gilad, Batia Stark, Shlomit Shalitin, Sarah Elitzur, Isaac Yaniv, Michal Yackobovitz-Gavan, Revital Houri-Shtrecher, Shlomit Barzilai, Galia Avrahami, Yael Lebenthal
Publikováno v:
Journal of pediatric endocrinologymetabolism : JPEM. 30(8)
Background:Survivors of acute lymphoblastic leukemia (ALL) may experience endocrine dysfunction. This study evaluated growth and pubertal patterns in survivors of childhood ALL.Methods:Longitudinal assessment of anthropometric measurements and pubert
The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia
Autor:
Martin Zimmermann, Batia Stark, Carmelo Rizzari, Jonas Abrahamsson, Brenda Gibson, Owen P. Smith, Ursula Creutzig, Dirk Reinhardt, Bassem I. Razzouk, Christine von Neuhoff, Petr Smisek, Rienk Y. J. Tamminga, Guy Leverger, Alexey Maschan, Yves Bertrand, Gertjan L. Kaspers, Henrik Hasle, Shau-Yin Ha, Michael Dworzak
Publikováno v:
Haematologica, 99(9), 1472-1478. Ferrata Storti Foundation
Haematologica, 99(9), 1472-1478. FERRATA STORTI FOUNDATION
Creutzig, U, Zimmermann, M, Dworzak, M N, Gibson, B, Tamminga, R, Abrahamsson, J, Ha, S Y, Hasle, H, Maschan, A, Bertrand, Y, Leverger, G, von Neuhoff, C, Razzouk, B, Rizzari, C, Smisek, P, Smith, OP, Stark, B, Reinhardt, D & Kaspers, G J L 2014, ' The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01 ', Haematologica, vol. 99, no. 9, pp. 1472-1478 . https://doi.org/10.3324/haematol.2014.104182
Creutzig, U, Zimmermann, M, Dworzak, M N, Gibson, B, Tamminga, R, Abrahamsson, J, Ha, S-Y, Hasle, H, Maschan, A, Bertrand, Y, Leverger, G, von Neuhoff, C, Razzouk, B, Rizzari, C, Smisek, P, Smith, O P, Stark, B, Reinhardt, D & Kaspers, G L 2014, ' The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia : results of the international study Relapsed AML 2001/01 ', Haematologica, vol. 99, no. 9, pp. 1472-8 . https://doi.org/10.3324/haematol.2014.104182
Haematologica, 99(9), 1472-1478. FERRATA STORTI FOUNDATION
Creutzig, U, Zimmermann, M, Dworzak, M N, Gibson, B, Tamminga, R, Abrahamsson, J, Ha, S Y, Hasle, H, Maschan, A, Bertrand, Y, Leverger, G, von Neuhoff, C, Razzouk, B, Rizzari, C, Smisek, P, Smith, OP, Stark, B, Reinhardt, D & Kaspers, G J L 2014, ' The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01 ', Haematologica, vol. 99, no. 9, pp. 1472-1478 . https://doi.org/10.3324/haematol.2014.104182
Creutzig, U, Zimmermann, M, Dworzak, M N, Gibson, B, Tamminga, R, Abrahamsson, J, Ha, S-Y, Hasle, H, Maschan, A, Bertrand, Y, Leverger, G, von Neuhoff, C, Razzouk, B, Rizzari, C, Smisek, P, Smith, O P, Stark, B, Reinhardt, D & Kaspers, G L 2014, ' The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia : results of the international study Relapsed AML 2001/01 ', Haematologica, vol. 99, no. 9, pp. 1472-8 . https://doi.org/10.3324/haematol.2014.104182
The prognostic significance of early response to treatment has not been reported in relapsed pediatric acute myeloid leukemia. In order to identify an early and easily applicable prognostic factor allowing subsequent treatment modifications, we asses
Autor:
C Korbijn, Martin Zimmermann, Atsushi Manabe, Lewis B. Silverman, Charles G. Mullighan, Veerle Mondelaers, Tim Lammens, C. Michel Zwaan, Gabriele Escherich, Ajay Vora, Giuseppe Basso, Shai Izraeli, Marry M. van den Heuvel-Eibrink, Martin Schrappe, Trudy Buitenkamp, James A. Whitlock, Kjeld Schmiegelow, Stephen P. Hunger, Renate Panzer-Grümayer, Maria Morak, Batia Stark, Nyla A. Heerema, Maurizio Aricò, Der-Cheng Liang, Georg Mann, Rob Pieters, Andrea Biondi, Hélène Cavé, Ching-Hon Pui, Erik Forestier, Jerzy Kowalczyk, Keizo Horibe, Karin R. Rabin, Ithamar Ganmore, Anthony V. Moorman, Gunnar Cario
Publikováno v:
Blood, 123(1), 70-77. American Society of Hematology
Children with Down syndrome (DS) have an increased risk of B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). The prognostic factors and outcome of DS-ALL patients treated in contemporary protocols are uncertain. We studied 653 DS-ALL patient
Autor:
Drorit, Luria, Eti, Rosenthal, David, Steinberg, Yona, Kodman, Marina, Safanaiev, Ninette, Amariglio, Smadar, Avigad, Batia, Stark, Shai, Izraeli, Weintraub, Michael
Publikováno v:
Cytometry Part B: Clinical Cytometry. :365-371
Background: Minimal residual disease (MRD) is a powerful prognostic indicator in childhood acute lymphoblastic leukemia (ALL). Multiparametric flow cytometry (FC) is a rapid and sensitive methodology for detection of MRD, applicable for most patients
Autor:
Drorit Luria, Isaac Yaniv, Dina Attias, Ran Steinberg, Batia Stark, Joseph Kapelushnik, Shifra Ash, Jerry Stein, Jacques Mardoukh, Gabriel Hertzel, Marta Jeison, Yacov Goshen, Galina Feinberg-Gorenshtein, Gili Halevy-Berko, Smadar Avigad, Ayelet Ben Barak
Publikováno v:
The American Journal of Pathology. 176:2616-2625
Although the role of MYCN amplification in neuroblastoma is well established, the biological and clinical characteristics of the 2p gain region harboring the MYCN gene remain unclear. The aim of this study was to compare the biological and clinical c
Autor:
Batia Stark, Dirk Reinhardt, Henrik Hasle, Christian M. Zwaan, Martin Zimmerman, Ursula Creutzig, Gertjan J.L. Kaspers, Michael Dworzak, Jan Stary
Publikováno v:
British Journal of Haematology, 148, 768-776. Wiley-Blackwell Publishing Ltd
British Journal of Haematology, 148(5), 768-776. Wiley-Blackwell
Zwaan, CM, Reinhardt, D, Zimmerman, M, Hasle, H, Stary, J, Stark, B, Dworzak, M, Creutzig, U & Kaspers, GJL 2010, ' Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study ', British Journal of Haematology, vol. 148, pp. 768-776 . https://doi.org/10.1111/j.1365-2141.2009.08011.x
Zwaan, C M, Reinhardt, D, Zimmerman, M, Hasle, H, Stary, J, Stark, B, Dworzak, M, Creutzig, U & Kaspers, G J L 2010, ' Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study ', British Journal of Haematology, vol. 148, no. 5, pp. 768-776 . https://doi.org/10.1111/j.1365-2141.2009.08011.x
British Journal of Haematology, 148(5), 768-776. Wiley-Blackwell
Zwaan, CM, Reinhardt, D, Zimmerman, M, Hasle, H, Stary, J, Stark, B, Dworzak, M, Creutzig, U & Kaspers, GJL 2010, ' Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study ', British Journal of Haematology, vol. 148, pp. 768-776 . https://doi.org/10.1111/j.1365-2141.2009.08011.x
Zwaan, C M, Reinhardt, D, Zimmerman, M, Hasle, H, Stary, J, Stark, B, Dworzak, M, Creutzig, U & Kaspers, G J L 2010, ' Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study ', British Journal of Haematology, vol. 148, no. 5, pp. 768-776 . https://doi.org/10.1111/j.1365-2141.2009.08011.x
Udgivelsesdato: 2009-Dec-8 The prognosis of children with relapsed/refractory acute myeloid leukaemia (AML) is poor, and new therapies are needed. Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody linked to the antitumor antibiotic calicheamicin. W